Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roman Perez-Soler

Showing results (11-20 of 81) with videos related to

Pageof 9
Sort By:
Drugs|March 1, 2014
Targeting angiogenesis in squamous non-small cell lung cancerBilal Piperdi, Amartej Merla, Roman Perez-Soler
Current Oncology Reports|December 6, 2001
Tyrosine kinase inhibitors: a clinical perspectiveSanjay Goel, Sridhar Mani, Roman Perez-Soler
Journal of Experimental Therapeutics & Oncology|November 28, 2007
EGFR inhibitor-mediated apoptosis in solid tumorsSanjay Goel, Manuel Hidalgo, Roman Perez-Soler
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2008
RETRACTED: Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR geneTianhong Li, Yi-He Ling, Roman Perez-Soler
Molecular Pharmacology|June 6, 2008
Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAKYi-He Ling, Ruoping Lin, Roman Perez-Soler
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2007
Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell linesBilal Piperdi, Yi-He Ling, Roman Perez-Soler
Seminars in Oncology|February 26, 2004
A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancerKatrina Y Glover, Roman Perez-Soler, Vassiliki A Papadimitradopoulou
Current Treatment Options in Oncology|March 5, 2016
Medical Treatment in Elderly Patients with Non-Small Cell Lung CancerKamila Bakirhan, Janaki Sharma, Roman Perez-Soler, et al.
The Journal of Biological Chemistry|June 25, 2003
Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cellsYi-He Ling, Leonard Liebes, Yiyu Zou, et al.
Cancer Chemotherapy and Pharmacology|January 9, 2009
Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinibYi-He Ling, Tianhong Li, Roman Perez-Soler, et al.
Pageof 9

Showing results (11-20 of 81) with videos related to

Sort By:
Pageof 9
Drugs|March 1, 2014
Targeting angiogenesis in squamous non-small cell lung cancerBilal Piperdi, Amartej Merla, Roman Perez-Soler
Current Oncology Reports|December 6, 2001
Tyrosine kinase inhibitors: a clinical perspectiveSanjay Goel, Sridhar Mani, Roman Perez-Soler
Journal of Experimental Therapeutics & Oncology|November 28, 2007
EGFR inhibitor-mediated apoptosis in solid tumorsSanjay Goel, Manuel Hidalgo, Roman Perez-Soler
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2008
RETRACTED: Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR geneTianhong Li, Yi-He Ling, Roman Perez-Soler
Molecular Pharmacology|June 6, 2008
Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAKYi-He Ling, Ruoping Lin, Roman Perez-Soler
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2007
Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell linesBilal Piperdi, Yi-He Ling, Roman Perez-Soler
Seminars in Oncology|February 26, 2004
A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancerKatrina Y Glover, Roman Perez-Soler, Vassiliki A Papadimitradopoulou
Current Treatment Options in Oncology|March 5, 2016
Medical Treatment in Elderly Patients with Non-Small Cell Lung CancerKamila Bakirhan, Janaki Sharma, Roman Perez-Soler, et al.
The Journal of Biological Chemistry|June 25, 2003
Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cellsYi-He Ling, Leonard Liebes, Yiyu Zou, et al.
Cancer Chemotherapy and Pharmacology|January 9, 2009
Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinibYi-He Ling, Tianhong Li, Roman Perez-Soler, et al.
Pageof 9